5 results
Improvement in OS is generally accepted as the best measure of clinical benefit forpatients with advanced/unresectable or metastatic NSCLC. The assumption thattreatment with MPDL3280A will prolong OS compared with treatment with docetaxel isbased on…
EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…
Primary Objective:- To provide continued access to atezolizumab based therapy and/or comparator agent(s) for eligible patients still on study treatment at the time of the parent study closure.Secondary Objectives:- Safety Objective: To evaluate the…
The co-primary objectives of this study are: * To evaluate the efficacy of as measured by investigator-assessed PFS according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). * To evaluate the efficacy of atezolizumab as…
Primary Efficacy ObjectiveThe primary efficacy objective of the study is as follows:• To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the…